December 18, 2018 / 6:07 AM / a month ago

BRIEF-Idorsia's Selatogrel Phase 2 Clinical Studies Meet Their Objective

Dec 18 (Reuters) - Idorsia Ltd:

* IDORSIA'S P2Y12 RECEPTOR ANTAGONIST - SELATOGREL - PHASE 2 CLINICAL STUDIES MEET THEIR OBJECTIVE

* IS NOW PREPARING FOR END OF PHASE 2 MEETINGS WITH HEALTH AUTHORITIES WHERE IT WILL DISCUSS PHASE 3 STUDY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below